A practical reference on Aib substitution: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
Peptide degradation follows several routes. Hydrolysis cleaves the backbone at susceptible residues, oxidation targets methionine and tryptophan side chains, and aggregation produces higher-molecular-weight species that are difficult to reverse. Light exposure accelerates oxidation, which is why amber glass or opaque secondary packaging is common. Repeated freeze-thaw cycles promote aggregation and are best avoided. Stability-indicating methods detect these changes before they become visible.
Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
With Angela Lombardi (University of Naples), Les Dutton and Michael Therien (Duke University) DeGrado has also designed numerous proteins that mimic many of the catalytic and electron relay properties of heme and non-heme iron proteins, including a transmembrane protein capable of shuttling electrons across membranes. His group has also designed the first examples of de novo ion and proton channels. Because the original approaches to de novo protein design focused on physical chemical principles it was easily extended to design biologically active polymers and foldamers (short homogeneous, sequence-specific polymers that fold into unique structures). This work led to the design of Brilacidin, which is currently in phase II clinical trials.
==== Fat ==== Based on the findings that FNDC5 induces thermogenin expression in fat cells, overexpression of FNDC5 in the liver of mice prevents diet-induced weight gain, and FNDC5 mRNA levels are elevated in human muscle samples after exercise, it has been proposed that irisin promotes the conversion of white fat to brown fat in humans, which would make it a health-promoting hormone. While this proposal has been challenged by evidence finding FNDC5 is upregulated only in highly active elderly humans, more recent literature has supported the hypothesis of FNDC5 and irisin having a necessary role in exercise related benefits.
French Guiana - Scouting in French Guiana Guadeloupe and Saint Martin - Scouting in Guadeloupe et Saint Martin Martinique - Scouts et Guides de Martinique Mayotte - Scouting in Mayotte New Caledonia - Scouting in New Caledonia Réunion - Scouting on Réunion Saint Pierre and Miquelon - Scouting in Saint Pierre and Miquelon Wallis and Futuna - Scouting in Wallis and Futuna New Zealand
==== Rapid expansion ==== By the end of 1858 there were already eight firms producing aniline dyes. By 1861 there were twenty-nine British patents on coloring matters from aniline. By 1864 68 firms were producing dyes. This was driven by the textile industry, which employed new designs requiring the colorful aniline dyes. Even Hofmann, who had at first criticized his student for leaving his academic research of quinine, later synthesized his own aniline dye, rosaniline. In 1858 the German chemist Johann Peter Griess obtained a yellow dye by reacting nitrous acid with aniline. It didn't last commercially, but it created even more interest in aniline as precursor for colorful compounds. French chemist François-Emmanuel Verguin reacted aniline with stannic chloride to yield fuchsine, a rose colored dye, the first of the triphenylmethane dyes. Further work by Hoffman along with the discovery of benzene’s structure (1858) and carbon’s tetravalency(1865), this science built the groundwork for modern organic chemistry. In the late 1860s many companies began offering a full spectrum of colors, and were already outcompeting many natural dyes for market share. Prices continually fell, and new colors and products regularly entered the market. On January 1, 1868, there were 52 producers of aniline dyes. Members of enlightened scientific societies from all over Europe including the Manchester Literary & Philosophical Society competed for expertise and authority with dyers and printers in factories and workshops.
=== Knockout studies === The large number of mouse compared to human FPR receptors makes it difficult to extrapolate human FPR functions based on genetic (e.g. gene knockout or forced overexpression) or other experimental manipulations of the FPR receptors in mice. In any event, combined disruption of the Fpr2 and Fpr3 genes causes mice to mount enhanced acute inflammatory responses as evidenced in three models, intestine inflammation caused by mesenteric artery ischemia-reperfusion, paw swelling caused by carrageenan injection, and arthritis caused by the intraperitoneal injection of arthritis-inducing serum. Since Fpr2 gene knockout mice exhibit a faulty innate immune response to intravenous listeria monocytogenes injection, these results suggest that the human FPR2 receptor and mouse Fpr3 receptor have equivalent functions in dampening at least certain inflammatory response.
Sources: en.wikipedia.org
== Dorsopathies (720–724) == 720 Ankylosing spondylitis and other inflammatory spondylopathies 720.0 Ankylosing spondylitis 720.1 Spinal enthesopathy 720.2 Sacroiliitis 721 Spondylosis and allied disorders 721.0 Cervical spondylosis w/o myelopathy 721.1 Cervical spondylosis, w/myelopathy 721.2 Thoracic spondylosis w/o myelopathy 721.3 Lumbosacral spondylosis w/o myelopathy 721.4 Thoracic or lumbar spondylosis w/ myelopathy 721.5 Kissing spine 721.6 Ankylosing vertebral hyperostosis 721.7 Traumatic spondylopathy 722 Intervertebral disc disorders 722.0 Displacement cervical intervertebral disc 722.1 Lumbar disc displacement w/o myelopathy 722.2 Degeneration of intervertebral disc site unspecified 722.3 Schmorl's nodes 722.4 Degenerative disc disease, cervical 722.5 Degeneration of thoracic or lumbar intervertebral disc 722.51 Degenerative disc disease, thoracic 722.52 Degenerative disc disease, lumbar 722.6 Degeneration of intervertebral disc, site unspecified Degenerative disc disease 722.7 Intervertebral disc disorder with myelopathy 722.8 Postlaminectomy syndrome 723 Other disorders of cervical region 723.0 Spinal stenosis in cervical region 723.1 Cervicalgia 723.2 Cervicocranial syndrome 723.3 Cervicobrachial syndrome (diffuse) 723.4 Brachial neuritis or radiculitis nos 723.5 Torticollis unspecified 723.6 Panniculitis specified as affecting neck 723.7 Ossification of posterior longitudinal ligament in cervical region 724 Other and unspecified disorders of back 724.0 Spinal stenosis, other than cervical 724.1 Pain in thoracic spine 724.2 Lumbago 724.3 Sciatica 724.4 Back pain w/ radiation, unspec. 724.5 Backache, unspecified 724.6 Disorders of sacrum 724.7 Disorders of coccyx 724.79 Coccygodynia 724.8 Other symptoms referable to back
Creatinine (; from Ancient Greek κρέας (kréas) 'flesh') is a breakdown product of creatine phosphate from muscle and protein metabolism. It is released at a constant rate by the body (depending on muscle mass).
Mriganka Sur (born 1953 in Fatehgarh, India) is an Indian-American neuroscientist known for his contributions to understanding the development, organization, plasticity and computational function of the cerebral cortex. He is the Newton Professor of Neuroscience and director of the Simons Center for the Social Brain at the Massachusetts Institute of Technology. He also served as a visiting faculty member in the Department of Computer Science and Engineering at the Indian Institute of Technology Madras and N.R. Narayana Murthy Distinguished Chair in Computational Brain Research at the Centre for Computational Brain Research, IIT Madras. He was on the Life Sciences jury for the Infosys Prize in 2010, and has served as jury chair since 2018.
These intraparietal haustoria, which penetrate partially into the algal cell wall but not into the cell membrane itself, allow short-distance shifting of photobiont cells and create pathways for carbohydrate translocation from the photosynthetic algae to the fungus. Unlike many other lichens, X. parietina can form several haustoria per algal cell, with each haustorium developed by either a single hypha or multiple fungal hyphae working together, enhancing the efficiency of the symbiotic relationship. Xanthoria parietina follows a four-stage life cycle with 13 developmental states. After spore germination, growth progresses through protothallus (fungal hyphae only), proterothallus (initial algal association), and juvenile stages, eventually forming a foliose thallus. In young thalli, apothecia cover about half of the thallus margin, but in mature thalli, they occupy only around 1/16 of the margin. This decrease indicates that as the lichen matures, the relative area devoted to reproductive structures declines compared to the overall thallus size. Environmental conditions strongly influence development—thalli in polluted or urban areas often fail to complete their life cycle, whereas those in clean habitats reach full maturity. Reproductive success varies by substrate—thalli on aspen trees produce more apothecia and spores than those on other species. Additionally, the mycobiont can associate with non-native algae (e.g., Pleurococcus) before establishing its typical Trebouxia or Pseudotrebouxia symbiont, enabling colonization across different substrates.
=== Companies === To translate his discoveries into therapeutics, Verdine has founded or co-founded numerous public biotech companies including Variagenics, Enanta, Eleven Bio, Tokai, Wave Life Sciences, and Aileron. He also founded the private company Gloucester Pharmaceuticals, which was acquired by Celgene in 2009. His companies share the mission of developing molecules intended to target “hard-to-drug” endogenous targets that have remained out of reach of modern cell-penetration technologies.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.